ImmunoPrecise Antibodies Ltd.

NASDAQ (USD): ImmunoPrecise Antibodies Ltd. (IPA)

Last Price

0.49

Today's Change

-0.018 (3.54%)

Day's Change

0.482 - 0.534

Trading Volume

757,468

Overview

Market Cap

22 Million

Shares Outstanding

45 Million

Avg Volume

6,284,386

Avg Price (50 Days)

0.45

Avg Price (200 Days)

0.74

PE Ratio

-0.66

EPS

-0.75

Earnings Announcement

12-Mar-2025

Previous Close

0.51

Open

0.51

Day's Range

0.482 - 0.534

Year Range

0.325 - 2.43

Trading Volume

772,216

Price Change Highlight

1 Day Change

-2.40%

5 Day Change

11.14%

1 Month Change

-6.19%

3 Month Change

12.68%

6 Month Change

-32.07%

Ytd Change

10.18%

1 Year Change

-76.94%

3 Year Change

-90.77%

5 Year Change

-77.36%

10 Year Change

2442.30%

Max Change

561.01%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment